SurModics Pharmaceuticals, which was formed following the acquisition of Brookwood Pharmaceuticals in July 2007, is a product-focused player in drug delivery, providing a range of technology solutions to
The agreement is part of UCB‘s strategy to optimise its manufacturing network in line with the evolution of its portfolio and includes the manufacturing sites of Monheim and
Alcon‘s board of directors approved a merger agreement with Novartis. Under the terms of the agreement, the merger consideration will include up to 2.8 Novartis shares and a
The main focus of Bayer HealthCare is on antibodies, coagulation factors and other therapeutic proteins. According to Bayer the building will be a multipurpose facility with great flexibility,
The study will investigate the safety and efficacy of Bepotastine besilate, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal
The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients
Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management
Under the agreement, Healthscreen will provide a range of important clinical measurements to Sanofi-aventis to offer assistance in research activities. Healthscreen said that the partnership will assist the
The agreement grants DSM rights to c-LEcta’s proprietary alcohol dehydrogenases for enzyme screening programs and development of sustainable manufacturing routes for manufacturing of pharmaceutical active ingredients and intermediates.
The unique identifier codes will be applied to several Unichem medicines, including Trika for the treatment of anxiety and Losar for the treatment of high blood pressure and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.